Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 3,155 matching trials from the live ClinicalTrials.gov search.

Filters: San Antonio, Texas Clear all

Conditions: Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Locally Advanced Rectal Adenocarcinoma
Interventions: Capecitabine, 5-fluorouracil, Leucovorin calcium, Irinotecan, Oxaliplatin, Long Course Chemoradiotherapy, Computed Tomography, Magnetic Resonance Imaging, Sigmoidoscopy, biopsy; Drug · Radiation · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2037
U.S. locations: 679
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 483 more

Conditions: Herpes Simplex
Interventions: acyclovir; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 0 Years to 28 Days
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 26
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 21 more

Conditions: Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma, Stage 2A Neuroblastoma, Stage 2B Neuroblastoma, Stage 3 Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, External Beam Radiation Therapy, Filgrastim, Laboratory Biomarker Analysis, Melphalan, Mesna, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Topotecan Hydrochloride, Vincristine Sulfate; Procedure · Drug · Radiation + 2 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 113
States / cities: Birmingham, Alabama • Downey, California • Duarte, California + 90 more

Conditions: Advanced Solid Tumors
Interventions: BAY2416964; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 4
States / cities: New Haven, Connecticut • Greenville, South Carolina • Houston, Texas + 1 more

Conditions: Breast Cancer
Interventions: docetaxel, paclitaxel; Drug
Lead sponsor: Aventis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2004
U.S. locations: 32
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 28 more

Conditions: Alzheimer Disease, Cognitive Impairment, Mild Cognitive Impairment, Dementia, Mild, Dementia Moderate, Dementia Alzheimers, Dementia of Alzheimer Type, AD
Interventions: Sensory Stimulation System (GS120) - Active; Device
Lead sponsor: Cognito Therapeutics, Inc.; Industry
Eligibility: 50 Years to 92 Years
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 53
States / cities: Phoenix, Arizona • Sun City, Arizona • Anaheim, California + 48 more

Conditions: Leukemia
Interventions: filgrastim, sargramostim, cytarabine, daunorubicin hydrochloride; Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 56 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 98
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more

Conditions: HIV, HIV Infections
Interventions: E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF, RTV, ATV, FTC/TDF, COBI; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 1,443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 91
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more

Conditions: Gingivitis, Plaque, Calculus, Dental
Interventions: RF-utilizing powered toothbrush, Control placebo with no RF; Device
Lead sponsor: Home Skinovations Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Anxiety, Pediatric ALL, Procedural Anxiety
Interventions: Ketamine 100 MG/ML, Midazolam 5 MG/ML; Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 2 Years to 12 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Diabetes Mellitus
Interventions: BGP-15 100 mg QD, BGP-15 100 mg BID, Placebo BID, BGP-15 200 mg QD, BGP-15 200 mg BID, BGP-15 400 mg QD; Drug
Lead sponsor: N-Gene Research Laboratories, Inc.; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Los Angeles, California • Paramount, California • Tustin, California + 17 more

Conditions: Leukemia
Interventions: cyclophosphamide, fludarabine phosphate; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 215
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 140 more

Conditions: Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
Interventions: Efgartigimod PH20 SC; Biological
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 18
States / cities: Phoenix, Arizona • Beverly Hills, California • Orange, California + 15 more

Conditions: Necrotizing Soft Tissue Infections, Necrotizing Fasciitis, Fournier's Gangrene
Interventions: AB103 0.5 mg/kg, NaCl 0.9%; Drug · Other
Lead sponsor: Atox Bio Ltd; Industry
Eligibility: 12 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 61
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more

Conditions: Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: BMS-247550; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 23
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 15 more

Conditions: Plasma Cell Myeloma Recurrent
Interventions: Isatuximab IV, Isatuximab SC, Dexamethasone, Pomalidomide, Montelukast, Paracetamol / Acetaminophen, Diphenhydramine, Methylprednisolone; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 13
States / cities: Aurora, Colorado • Jacksonville, Florida • Plantation, Florida + 10 more

Conditions: Gout, Hyperuricemia, Gout Flare, Tophi
Interventions: Tigulixostat, Allopurinol, Placebo; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 2,202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 124
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 91 more

Conditions: Metastatic Solid Tumor, Advanced Solid Tumor
Interventions: CHS-114, Toripalimab, 5 Fluorouracil, Cisplatin; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 20
States / cities: Tucson, Arizona • Duarte, California • Aurora, Colorado + 16 more

Conditions: Chronic Kidney Disease, Hemodialysis Access, Arteriovenous Fistula, End Stage Renal Disease (ESRD)
Interventions: Velocity Percutaneous Arteriovenous Fistula; Device
Lead sponsor: Venova Medical; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 13
States / cities: Dothan, Alabama • Concord, California • Riverside, California + 9 more

Conditions: End Stage Renal Disease
Interventions: Triferic; Drug
Lead sponsor: Rockwell Medical Technologies, Inc.; Industry
Eligibility: Up to 17 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 9
States / cities: Birmingham, Alabama • Loma Linda, California • Stanford, California + 6 more

Conditions: Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions: Botensilimab, Balstilimab; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 17
States / cities: Scottsdale, Arizona • Duarte, California • Los Angeles, California + 9 more

Conditions: Prostatic Neoplasms
Interventions: Leuprolide acetate; Drug
Lead sponsor: Abbott; Industry
Eligibility: Male only
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 55
States / cities: Homewood, Alabama • Huntsville, Alabama • Anchorage, Alaska + 49 more

Conditions: Ovarian Cancer
Interventions: Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 50 Years to 74 Years · Female only
Enrollment: 8,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2028
U.S. locations: 12
States / cities: Miami, Florida • Des Moines, Iowa • Minneapolis, Minnesota + 8 more

Conditions: Overactive Bladder, Lower Urinary Tract Symptoms
Interventions: Behavioral training, Tolterodine + tamsulosin, Combined Behavioral + Drug Therapy; Behavioral · Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 40 Years and older · Male only
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 3
States / cities: Birmingham, Alabama • Atlanta, Georgia • San Antonio, Texas

Search by objective public record fields.

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response

Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving the Central Nervous System

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer

Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer

Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)

S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

Safety and Efficacy of the ToothWave -12 Weeks Calculus Study

Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections

S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Pivotal Study of the Velocity™ pAVF System

Triferic Pediatric Pharmacokinetic Protocol

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer

Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women

Combined Behavioral and Drug Treatment of Overactive Bladder in Men